The obesity-drug market is accelerating, with global sales projected to reach $130–150 billion by the mid-2030s. Eli Lilly is extending its lead with a strong pipeline, while Novo Nordisk faces slowing growth and pricing pressure. Competition is rising as Amgen, AstraZeneca, Pfizer, and Wave Life Sciences enter the race, with Wave’s stock soaring after positive early-stage trial data.